US20180028575A1 - Methods and compositions for treatment of penile defects - Google Patents
Methods and compositions for treatment of penile defects Download PDFInfo
- Publication number
- US20180028575A1 US20180028575A1 US15/541,988 US201615541988A US2018028575A1 US 20180028575 A1 US20180028575 A1 US 20180028575A1 US 201615541988 A US201615541988 A US 201615541988A US 2018028575 A1 US2018028575 A1 US 2018028575A1
- Authority
- US
- United States
- Prior art keywords
- stem cells
- penile
- composition
- canceled
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 176
- 238000000034 method Methods 0.000 title claims abstract description 91
- 230000007547 defect Effects 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims description 37
- 210000000130 stem cell Anatomy 0.000 claims abstract description 198
- 210000003899 penis Anatomy 0.000 claims abstract description 63
- 208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 42
- 201000001881 impotence Diseases 0.000 claims abstract description 42
- 208000004362 Penile Induration Diseases 0.000 claims abstract description 33
- 208000020758 Peyronie disease Diseases 0.000 claims abstract description 33
- 239000003102 growth factor Substances 0.000 claims abstract description 25
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 24
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 24
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 24
- 210000004369 blood Anatomy 0.000 claims abstract description 23
- 239000008280 blood Substances 0.000 claims abstract description 23
- 210000004623 platelet-rich plasma Anatomy 0.000 claims abstract description 23
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 21
- 210000004381 amniotic fluid Anatomy 0.000 claims abstract description 18
- 210000001691 amnion Anatomy 0.000 claims abstract description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 6
- 210000001519 tissue Anatomy 0.000 claims description 52
- 102000008186 Collagen Human genes 0.000 claims description 27
- 108010035532 Collagen Proteins 0.000 claims description 27
- 229920001436 collagen Polymers 0.000 claims description 27
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 20
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 20
- 239000000854 Human Growth Hormone Substances 0.000 claims description 20
- 210000005226 corpus cavernosum Anatomy 0.000 claims description 18
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 16
- 230000004862 vasculogenesis Effects 0.000 claims description 15
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 14
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 14
- 230000029663 wound healing Effects 0.000 claims description 14
- 208000014674 injury Diseases 0.000 claims description 13
- 230000033115 angiogenesis Effects 0.000 claims description 12
- 230000008733 trauma Effects 0.000 claims description 11
- 201000011264 priapism Diseases 0.000 claims description 8
- 229960003604 testosterone Drugs 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 7
- 229960004532 somatropin Drugs 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 210000003668 pericyte Anatomy 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 108060005980 Collagenase Proteins 0.000 abstract description 13
- 102000029816 Collagenase Human genes 0.000 abstract description 13
- 239000000654 additive Substances 0.000 abstract description 13
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 4
- 239000000306 component Substances 0.000 abstract 1
- 239000003357 wound healing promoting agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 74
- 210000000577 adipose tissue Anatomy 0.000 description 45
- 210000001367 artery Anatomy 0.000 description 33
- 238000002513 implantation Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 230000000996 additive effect Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 101710163391 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase Proteins 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000007443 liposuction Methods 0.000 description 8
- 230000003169 placental effect Effects 0.000 description 8
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 8
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001172 regenerating effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 4
- 229960000711 alprostadil Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 210000003195 fascia Anatomy 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007926 intracavernous injection Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000005059 placental tissue Anatomy 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- -1 antibodies Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- ZKVLEFBKBNUQHK-UHFFFAOYSA-N helium;molecular nitrogen;molecular oxygen Chemical compound [He].N#N.O=O ZKVLEFBKBNUQHK-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 229960001789 papaverine Drugs 0.000 description 3
- 229960001999 phentolamine Drugs 0.000 description 3
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010070653 Penile curvature Diseases 0.000 description 2
- 206010070652 Penile plaque Diseases 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 229940015688 caverject Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229940013191 edex Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000009986 erectile function Effects 0.000 description 2
- 210000005225 erectile tissue Anatomy 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102100034594 Angiopoietin-1 Human genes 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100029761 Cadherin-5 Human genes 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 1
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
- 108010013295 Microbial collagenase Proteins 0.000 description 1
- ZZIKIHCNFWXKDY-UHFFFAOYSA-N Myriocin Natural products CCCCCCC(=O)CCCCCCC=CCC(O)C(O)C(N)(CO)C(O)=O ZZIKIHCNFWXKDY-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000366596 Osiris Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000022034 Penile disease Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 102100040120 Prominin-1 Human genes 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010021093 hypospadias Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ZZIKIHCNFWXKDY-GNTQXERDSA-N myriocin Chemical compound CCCCCCC(=O)CCCCCC\C=C\C[C@@H](O)[C@H](O)[C@@](N)(CO)C(O)=O ZZIKIHCNFWXKDY-GNTQXERDSA-N 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229930189672 pseudopterosin Natural products 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940022743 xiaflex Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the present invention relates to compositions for use in medical procedures, methods for use thereof, and methods of preparation thereof. More specifically, the invention relates to compositions including stem cells, such as penile stem cells, useful for regenerating tissue, improving vasculogenesis and angiogenesis in disease and improving wound healing, specifically in penile disease and defects.
- stem cells such as penile stem cells
- stem cells have been suggested as a cure for ailments ranging from Parkinson's disease (replacing dying dopaminergic cells of the substantia nigra) to myocardial infarctions and cardiomyopathy. Gimble J M et al., Circulation Res. 2007; 100: 1249-1260; Kondo K et al., Arteriosclerosis, Thrombosis, and Vascular Biol. 2009; 29: 61-66.
- ED erectile dysfunction
- PD Peyronie's disease
- At least some forms of ED trace their etiology to vascular deficits in the penile tissue.
- Pharmaceutical compositions for treating ED do exist; however, a need exists for a treatment that does not require use of medicaments.
- At least one group has reported success in the use of stem cells derived from bone marrow to reverse ED in an animal model. Kendirci M et al., J. Urol. 2010; 184(4): 1560-1566. Another group has seen success in using muscle-derived stem cells in a rat model of ED. Woo J C et al., Korean J. Urol. 2011; 52: 359-363.
- Peyronie's disease is an ailment involving the growth of fibrous plaques in the soft tissue of the penis. These plaques grow in the tunica albuginea, a region of connective tissue that is part of the more general connective tissue of Buck's fascia.
- the tunica albuginea is an area surrounding the corpora cavernosa.
- the disease results in pain, ED, scarring, and alteration of penis shape, and may be caused by disorganized collagen fibers.
- Treatments for the disease currently include administration of corticosteroids to the plaques, radiation therapy, and vitamin E Pharmaceuticals for treatment exist; however, the use of medicaments is considered controversial in the art, and these compounds have not met with sustained success.
- Hauck E W et al. European Urology 2006; 49(6): 987-97.
- the newest medication is Clostridium Histolyticum Collagenase which has potentially harmful side effects.
- compositions such as compositions of stem cells, that are easy to obtain and isolate, methods for obtaining such stem cells, and methods for using stem cells in treating penile defects.
- compositions that comprise a population of isolated penile stem cells substantially free of red blood cells.
- the penile stem cells are derived from a donor.
- the penile stem cell is mixed with amniotic fluid.
- compositions that comprise adipose tissue and isolated stem cells.
- the isolated stem cells are a population of isolated penile stem cells substantially free of red blood cells.
- the penile stem cell is derived from a donor, either alive or dead, such as a cadaver.
- the isolated stem cells include stem cells placental or embryonic in origin.
- the isolated stem cells include mesenchymal stem cells.
- the isolated stem cells include adipose-derived stem and regenerative cells (ADRC).
- ADRC adipose-derived stem and regenerative cells
- the stem cells and adipose tissue are derived from a donor.
- the compositions include at least one additional additive.
- the additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis.
- the compositions include a growth scaffold.
- the penile stem cells are mixed with amnion and/or amniotic fluid, or growth factors, or testosterone, or human chorionic gonadotropin (HCG), or human growth hormone (HGH) or a combination thereof.
- compositions that include a population of isolated penile stem cells, and implanting the composition within the penis of the subject.
- the penile stem cells are derived from the subject.
- the penile stem cells are mixed with amnion and/or amniotic fluid.
- the compositions comprise adipose tissue and stem cells, preferably penile stem cells that are derived from the subject.
- the compositions include stem cells placental or embryonic in origin.
- the penile stem cells are mesenchymal stem cells.
- the compositions include ADRC.
- the adipose tissue and ADRC are derived from the subject.
- the composition is implanted into the subject's penis.
- the composition is implanted into or around the subject's corpus cavernosum.
- the composition is implanted into or around the subject's tunica albuginea.
- the composition is injected into the tissue of interest.
- the composition is injected or infused into any artery that feeds penile tissue.
- the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- compositions include stem cells placental or embryonic in origin.
- the penile stem cells are mesenchymal stem cells.
- the composition is implanted into the subject's penis.
- the composition is implanted into or around the subject's corpus cavernosum.
- the composition is implanted into or around the subject's tunica albuginea.
- the composition is injected into the tissue of interest.
- the composition is injected or infused into any artery that feeds penile tissue.
- the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- compositions that are implanted include at least one additional additive.
- the additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis.
- the composition includes an implantable or injectable growth scaffold, or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action.
- the present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising at least one penile stem cell, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment.
- the present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising amnion and/or amniotic fluid, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment.
- methods of obtaining penile stem cells substantially free of red blood cells comprising the steps of: providing a whole blood specimen obtained from the penis of a subject; separating the whole blood into fractions, wherein one fraction contains penile stem cells and a second fraction containing substantially all of the red blood cells from the specimen; and collecting the fraction containing the penile stem cells.
- compositions that comprise a population of isolated penile stem cells substantially free of red blood cells.
- the penile stem cells are derived from a donor or cadaver.
- the penile stem cell is mixed with amniotic fluid.
- the cells are cultured and grown and then reinjected.
- compositions that comprise adipose tissue and isolated stem cells.
- the isolated stem cells are a population of isolated penile stem cells substantially free of red blood cells.
- the penile stem cell is derived from a donor or cadaver.
- the isolated stem cells include stem cells placental or embryonic in origin.
- the isolated stem cells include mesenchymal stem cells.
- the isolated stem cells include adipose-derived stem and regenerative cells (ADRC).
- ADRC adipose-derived stem and regenerative cells
- the stem cells and adipose tissue are derived from a donor.
- compositions include at least one additional additive.
- the additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis.
- the compositions include a growth scaffold or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action.
- the penile stem cell is mixed with amniotic fluid.
- compositions that include a population of isolated penile stem cells, and implanting the composition within the penis of the subject.
- the penile stem cells are derived from the subject.
- the penile stem cells are mixed with amnion and/or amniotic fluid.
- the compositions comprise adipose tissue and stem cells, preferably penile stem cells that are derived from the subject.
- the compositions include stem cells placental or embryonic in origin.
- the penile stem cells are mesenchymal stem cells.
- the compositions include ADRC.
- the adipose tissue and ADRC are derived from the subject.
- the composition is implanted into the subject's penis.
- the composition is implanted into or around the subject's corpus cavernosum.
- the composition is implanted into or around the subject's tunica albuginea.
- the composition is injected into the tissue of interest.
- the composition is injected or infused into any artery that feeds penile tissue.
- the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- compositions include stem cells placental or embryonic in origin.
- the penile stem cells are mesenchymal stem cells.
- the composition is implanted into the subject's penis.
- the composition is implanted into or around the subject's corpus cavernosum.
- the composition is implanted into or around the subject's tunica albuginea.
- the composition is injected into the tissue of interest.
- the composition is injected or infused into any artery that feeds penile tissue.
- the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- compositions that are implanted include at least one additional additive.
- the additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis.
- the composition includes an implantable or injectable growth scaffold, or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action.
- the present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising at least one penile stem cell, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment.
- the present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising amnion and/or amniotic fluid, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment.
- the extracellular matrix component(s) and/or growth factor(s) are placental or embryonic, amniotic or chorionic, or cadaveric in origin.
- methods of obtaining penile stem cells substantially free of red blood cells comprising the steps of: providing a whole blood specimen obtained from the penis of a subject; separating the whole blood into fractions, wherein one fraction contains penile stem cells and a second fraction containing substantially all of the red blood cells from the specimen; and collecting the fraction containing the penile stem cells.
- the stem cells are penile stem cells derived from the subject. In some embodiments, the penile stem cell is mixed with amniotic fluid. In certain embodiments, the composition comprises adipose tissue and stem cells, preferably penile stem cells, which may be derived from the subject. In some embodiments, the compositions include one or more additional types of stem cells. In some embodiments, the additional types of stem cells are placental or embryonic in origin. In other embodiments, the additional types of stem cells are mesenchymal stem cell. In certain further embodiments, the additional types of stem cells are ADRCs In further embodiments, the adipose tissue and ADRC are derived from the subject. In some embodiments, the composition is implanted into the subject's penis.
- the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- the composition that is implanted includes at least one additional additive or is only an additive of growth factors such as amniotic fluid.
- the additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis.
- the composition includes an implantable or injectable growth scaffold.
- Penile stem cells may be used to advantageously promote vasculogenesis and wound healing in penile defects. These properties function to address defects and diseases such as ED. Additionally, penile stem cells may be provided directly to plaques in Peyronie's disease, stimulating wound healing. Penile stem cells are preferable for stem cell derived treatments of these defects because of their ability to stimulate vasculogenesis and to produce organized collagen.
- composition of the present invention includes testosterone.
- a composition of the present invention includes human chorionic gonadotropin (hCG).
- hCG human chorionic gonadotropin
- a composition of the present invention includes human growth hormone (HGH) or somatropin.
- HGH human growth hormone
- somatropin somatropin
- a composition of the present invention includes collagen.
- stem cell refers to any multipotent or pluripotent cell, traditional stem cells, progenitor cells, preprogenitor cells, and reserve cells. These cells include Mesenchymal Stem Cells, Hematopoietic Stem Cells, Endothelial Stem Cells, and Pericytes. The term is used interchangeably with and may mean progenitor cell.
- a stem cell may be derived from an adult organism or from a cell line, or from an embryonic organism.
- Exemplary stem cells include embryonic stem cells, adult stem cells, pluripotent stem cells, neural stem cells, liver stem cells, muscle stem cells, muscle precursor stem cells, endothelial progenitor cells, bone marrow stem cells, chondrogenic stem cells, lymphoid stem cells, mesenchymal stem cells, hematopoietic stem cells, and the like. Descriptions of stem cells, including method for isolating and culturing them, may be found in, among other places, Embryonic Stem Cells, Methods and Protocols, Turksen ed., Humana Press, 2002.
- adult refers to any non-embryonic organism.
- adult adipose-derived regenerative cell refers to an adipose-derived regenerative cell, other than that obtained from an embryo.
- embryo refers to any multicellular diploid eukaryote during development, until birth or hatching.
- embryonic stem cell refers to a pluripotent cell derived from the inner cell mass of a blastocyst.
- meenchymal stem cell refers to any multipotent stromal cell derived from, for example and without limitation, umbilical cord blood, adipose tissue, muscle, comeal stroma, and dental pulp that can differentiate into cells such as, including but not limited to, osteoblasts, chondrocytes, and adipocytes.
- ADRC adipose-derived regenerative cell
- ASC adipose stem cells
- ADRC are a heterologous population of cells comprising at least one of the following population of cells; adult stem cells, vascular endothelial cells, vascular smooth muscle cells, endothelial cells, mesenchymal stem cells, fibroblasts, pericytes and additional other cell types.
- ADRC refers to a substantially pure population of adipose-derived stem cells.
- ADRC can be easily harvested from adipose tissue and are substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells.
- the stromal vascular fraction cells are substantially devoid of extracellular matrix material from adipose tissue.
- ADRC may also be referred to as adipose-derived stem/stromal cells (ASCs), adipose-derived adult stem (ADAS) cells, adipose-derived adult stromal cells, adipose-derived stromal cells, adipose stromal cells, adipose mesenchymal cells, adipose-derived mesenchymal stem cells, lipoblasts, pericytes, preadipocytes, and processed lipoaspirate cells.
- ASCs adipose-derived stem/stromal cells
- ADAS adipose-derived adult stem
- ADAS adipose-derived adult stem
- adipose-derived adult stromal cells adipose-derived stromal cells
- adipose stromal cells adipose mesenchymal cells
- lipoblasts pericytes
- preadipocytes preadipocytes
- adipose refers to any fat tissue from a subject.
- the terms “adipose” and “adipose tissue” are used interchangeably herein.
- the adipose tissue may be brown fat, white fat or yellow fat or white adipose tissue, derived from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue site.
- the adipose tissue has adipocytes and stroma.
- Adipose tissue is found throughout the body of an animal. For example, in mammals, adipose tissue is present in the omentum, bone marrow, subcutaneous space, and surrounding most organs. Such cells may comprise a primary cell culture or an immortalized cell line.
- the adipose tissue may be from any organism having fat tissue.
- the adipose tissue is human; most preferably, the adipose tissue is derived from the individual in need of treatment for a penile defect.
- a convenient source of adipose tissue is from liposuction surgery, however, the source of adipose tissue or the method of isolation of adipose tissue is not critical to the invention, and acquisition of adipose tissue by any means may adequately provide tissue and stem cells for the present invention.
- tissue as used herein is a broad term that is applied to any group of cells that perform specific functions, and includes in some instances whole organs and/or part of organs.
- a tissue need not form a layer, and thus encompasses a wide range of tissue, including adipose tissue derived from any source in an organism.
- the tissue is derived from a mammal.
- the tissue is derived from the individual in need of treatment for a penile defect.
- implant refers to any method for transferring a population of cells or cell mass into a subject, including by surgical implantation (incision into the tissue of interest and deposition therein) and injection by a syringe, needle, cannula, or the like of any suitable gauge.
- An implant as used herein can comprise genetically modified cells, as well as cells differentiated from other cells, such as stem cells, progenitors, and the like, as well as adipose cells or tissue.
- corpus cavernosum of the penis refers to one of a pair of sponge-like regions of erectile tissue which contain most of the blood in the penis during penile erection.
- the two corpus cavernosum and a corpus spongiosum are three expandable erectile tissues along the length of the penis which fill with blood during erection.
- the term “corpus” is used interchangeably herein with corporal, corporeal and corporic, which are terms used to describe tissues which are derived from the corpora cavernosum or which can be developed, differentiated, or altered by natural or artificial means into corpora cavernosum tissue.
- cavernosum is used interchangeably herein as cavernae, corporum, cavernosum, or cavernosorum penis, and refers to the caverns of corpora cavernosa (or one of the two corpus cavernosum) of the penis or the dilatable spaces within the corpus cavernosum of the penis, which fill with blood and become distended with erection.
- tissue albuginea refers to the fibrous tissue covering, or enveloping, the corpora cavernosa of the penis. This tissue consists of elastin and collagen.
- Bow's fascia refers to the layer of fascia covering the penis, including the tunica albuginea.
- subject and “individual” are used interchangeably herein, and refer to an animal, for example a human, from whom stem cells, for example penile stem cells can be harvested, or a subject into whom tissue can be transplanted for treatment, for example treatment for penile defects, using the compositions and methods described herein.
- stem cells for example penile stem cells
- tissue can be transplanted for treatment, for example treatment for penile defects, using the compositions and methods described herein.
- tissue for example treatment for penile defects, using the compositions and methods described herein.
- the term “subject” refers to that specific animal.
- the subject is a human subject. It is possible in embodiments of this invention that recipient subjects are of a different mammalian subject than the donor subject.
- compositions comprise a population of isolated penile stem cells.
- the composition is one that is suitable for implantation into a subject, for example an animal, preferably a mammal.
- the composition is suitable for implantation into a human.
- the at least one penile stem cell of the composition is suitable for implantation into a human because they are derived from the same human subject.
- compositions that comprises adipose tissue and a population of isolated stem cells, such as a penile stem cell.
- the composition is one that is suitable for implantation into a subject, for example an animal, preferably a mammal.
- the composition is suitable for implantation into a human.
- the adipose tissue and at least one stem cell of the composition are suitable for implantation into a human because they are derived from the same human subject.
- Stem cells include, but are not limited to, mesenchymal stem cells.
- the stem cells may be obtained from any suitable source, for example, and without limitation, stem cells may be obtained from adult or embryonic sources, from bone marrow, from placental tissue, from umbilical cord blood, and from adipose tissue.
- the stem cell is obtained from adipose tissue, and is an adipose-derived regenerative cell (ADRC).
- ADRC adipose-derived regenerative cell
- the stem cell is obtained from the penis, and is a penile stem cell.
- adipose tissue may be collected in any suitable manner
- adipose tissue is obtained through dry liposuction, wet liposuction, super-wet liposuction, tumescent liposuction, power-assisted liposuction, laser-assisted liposuction, or the like.
- adipose tissue may be processed by known methods. The following methods are to be considered exemplary.
- adipose tissue is processed using the STEMSOURCE® Cellbank or Cytori Celution System. The Cytori procedure and system therefore are disclosed in detail in U.S. Pat. Nos. 7,501,115 and 7,687,059.
- adipose tissue is harvested from a subject.
- the subject is an individual in need of treatment for a penile defect.
- the tissue is processed to remove mature adipocytes and connective tissue from the sample. Processing may occur within a system having a tissue collection port, filter disposed within the system, and a mixing container for holding the processed sample. The filter works to remove the unwanted cells and non-cellular materials from the sample, enriching the proportion of ADRCs in the filtered sample.
- the Cytori system has successfully been used in providing ADRCs for breast tissue implantation for reconstruction after radical lumpectomy, proving the ability of stem cells isolated by this method to generate tissue of a single type (adipocytes, or fat). Similarly, in treatment of penile defects, only one type of tissue need be generated. As such, the Cytori method and system is well suited for use in preparing a composition of the current invention. With regard to use of the Cytori system and method itself, processing is accomplished by washing and disaggregating the tissue to reduce the presence of free lipids and blood elements. Processing may or may not also include a rinsing step; the step conducted using isotonic saline or any other suitable physiologic solution known to those skilled in the art.
- Remaining tissue is then disaggregated using enzyme degradation or mechanical disaggregation.
- the cells and solution are then centrifuged to separate cells, including ADRC, from the degradation solution.
- the cells form a pellet in the centrifuge, and the pellet can be frozen for storage or resuspended in another solution, for example a buffer, for use in medical treatments such as those recited herein.
- the concentration of stem cells obtained by this method may vary, but typically approximately 0.1% of the cells in the pellet are stem cells. Greater percentages may be obtained by varying the above method, for example by use of adherence protocols such as described in Berdel W E et al., Purification of human monocytes by adherence to polymeric fluorocarbon. Immunobiology 1982 163(5): 511-520, or by separation on the basis of cell-surface markers, for example on the basis of markers present on differentiated cells, such as CD34 and the like, or by selecting based on markers expressed on progenitor cells, such as CD90 and the like. In a preferred, embodiment, the percentage of stem cells present in the pellet is between approximately 2% and 12%.
- composition may further comprise immunosuppressive agents designed to prevent rejection of the composition once implanted.
- Immunosuppressive agents may be selected from glucocorticoids, cytostatics, antibodies, pharmaceuticals such as tacrolimus, ciclosporin, sirolimus, interferons, opioids, mycophenolic acid, fingolimod, and myriocin.
- adipose tissue is derived from lipoaspirate (i.e. from liposuction), is washed, exposed to a collagenase digest at 37° Celsius, and centrifuged.
- penile stem cell isolation procedures are provided herein, the invention described should not be limited to those procedures. It should be apparent to those skilled in the art that other means of isolating stem cells, in particular penile stem cells, are possible and may be used interchangeably with the current invention.
- penis stem cells can be isolated from tissue obtained from a biopsy of the penis by a variety of techniques, such as by using an 18 gauge needle biopsy gun. They can also be obtained via a trocar or needle by draining blood and fluid from an erect penis from the patient then processed, activated, and/or minimally manipulated and placed back into the subject's penis
- penile stem cells may be isolated from a whole blood sample obtained from the penis of a subject by preparing and extracting the platelet rich plasma preparation, which contains the penile stem cells, from the specimen. This is a similar method used to obtaining bone marrow stem cells.
- the U.S. Food and Drug Administration has approved two methods for platelet rich plasma (PRP) preparation. Both methods involve the collection of whole blood (with the anticoagulant citrate dextrose) and two stages of centrifugation designed to separate PRP from platelet-poor plasma and red blood cells.
- PRP platelet rich plasma
- skin is prepared in a sterile manner for drawing blood.
- the blood is gently drawn or aspirated into an anticoagulated syringe, such as a 20 cc syringe. Care is taken to not activate the platelets or rupture the RBCs.
- the first spin separates red blood cells (RBC) from the PRP and the RBCs are discarded.
- the second spin concentrates platelets and white cells with the supernatant being platelet poor plasma (PPP), which is removed. The remaining plasma is used to resuspend the platelets and white cells.
- about 60 cc of anticoagulated blood drawn and processed about 10 cc of PRP is obtained.
- the PRP can be used directly for reinjection into the penis.
- the PRP can also be added to or enriched with other types of stem cells, such as those discussed below.
- the PRP is centrifuged and the penile stem cells pelleted and then resuspended in a suitable media.
- PRP or penile stem cells are mixed with growth factors such as amnion or amniotic fluid or other biologic or non-biologic growth factors, such as platelet derived growth factor or endothelial derived growth factor or testosterone, human chorionic gonadotropin (hCG), human growth hormone (HGH) or somatropin.
- the penile stem cells are mixed with Natural Killer (NK cells) harvested from the subject.
- the penile stem cells are resuspended with PRP containing autologous growth factors.
- the penile stem cells are resuspended in saline, such as phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- the penile stem cells are resuspended with a buffer, for example bicarbonate for a basic composition or phosphate for an acidic composition.
- the NK cells can dissolve peyronie's plaques.
- the penile stem cells and compositions described herein can be injected into the penile arteries or the urethral sphincter or layered on a flap externally or internally, or injected into a stricture or fistula or into the corpora cavernosum, bulbo spongiosum, or tunica albiginea or urethra. They can also be injected during open surgery for Peyronie's disease.
- the penile stem cells and compositions described herein are administered in the form of a gel or putty.
- the penile stem cells and compositions described herein are injected into the penis in the form of a spray.
- the penile stem cells and compositions described herein are formulated and administered for extended release (e.g., in the form of dissolvable capsules or pellets).
- the penile stem cells are isolated, the stem cells are expanded and then administered to the subject.
- the penile stem cells are isolated, formulated for long-term storage (e.g., by freezing) for use at a later date.
- ADRCs are harvested from the growth by flow cytometry according to traditional flow cytometry methods, for example as disclosed in Alexander C M et al., Cell Stem Cell 2009; 5: 579-83. Cells are washed in buffer (FBS) and incubated for 30 minutes in FBS with antibodies against CD105, CD90, CD34, and/or CD45. The ADRCs are then combined with adipose cells in a composition for injection.
- FBS buffer
- the ADRCs are processed by washing in PBS followed by ECM digestion in 0.075% collagenase for 30 minutes at 37 degrees Celsius. Digestion is neutralized using Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS. Digested tissue is then centrifuged at 1200 g for 10 minutes to obtain a cell pellet. The pellet is then resuspended and filtered, and cells are plated. Cell media is removed 12-18 hours later and fresh media provided. Cells are incubated on ice with antibodies to human CDllb, CD18, CD31, CD34, CD38, CD44, CD45, CD54, CD62L, CD90, CD105, CD106, CD117, CD133, CD144, CD166, and/or CD271. Cells are then washed and flow cytometry, for example fluorescence-activated cell sorting, is performed according to traditional, known methods, for example as disclosed in Alexander C M et al., Cell Stem Cell 2009; 5: 579-83.
- flow cytometry for
- the stem cells used in the present composition includes mesenchymal stem cell isolated from bone marrow.
- the bone marrow is that of the patient in need of treatment for a penile defect.
- Such stem cells may be isolated in accordance with the following protocol, which is to be considered exemplary.
- Bone marrow tissue may be obtained from the head of the femur, by transversally segmenting the femoral head to expose trabecular, or cancellous, bone.
- This trabecular bone may be extracted with successive, serial washes of phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- the solution of PBS and trabecular bone may then be filtered through a filter of any suitable pore diameter, for example and without limitation a 40, 70, or 100 um cell strainer.
- the solution may then be centrifuged at 400 g for 10 minutes to form a pellet of cells, the supernatant aspirated, and the pellet resuspended in media containing DMEM supplemented with 10% FBS and 1% streptomycin or penicillin, or both.
- Cells may then be cultured, and then washed with PBS to remove non-adherent cells.
- the obtained cells may be further expanded by repeating the incubation and washing steps until a suitable volume of cells is obtained.
- Medium may be supplemented with heparin and growth factors, if necessary.
- the stem cells may be obtained from placental tissue. Stem cells from this source may be obtained by any method known to those of skill in the art. In certain embodiments, stem cells may be obtained according to the following procedure. Tissue samples from placental tissue may be washed in PBS plus antibiotic solution (200 U/mL penicillin and/or 200 mg/mL streptomycin). The amnion is separated from chorion through fine dissection. Small pieces of both membranes are minced and subjected to enzymatic digestion to obtain a mesenchymal population of cells. The resulting cells are seeded in 25 cm culture flasks with 5 mL of DMEM with 20% FBS and antibiotics (penicillin 100 U/mL and/or streptomycin 100 mg/mL), and incubated at 37 degrees Celsius.
- No adherent cells are removed with changes of medium (DMEM plus 10% FBS).
- the obtained cells may be further expanded by repeating the incubation and washing steps until a suitable volume of cells is obtained.
- Medium may be supplemented with heparin and growth factors, if necessary.
- stem cells may be obtained from a suitable commercial source for use in the compositions of the present invention.
- mesenchymal stem cells from placental tissue provided under the trade name OVATION® by Osiris Therapeutics, Inc. may be used. This product is preferred because it includes components of extracellular matrix (ECM) and growth factors.
- ECM extracellular matrix
- the composition further comprises other agents.
- agents may include compositions designed to assist in reducing inflammation, aiding wound healing, promoting angiogenesis and/or vasculogenesis, and degrading collagen.
- Agents useful for reducing inflammation include, but are not limited to, anti-inflammatory cytokines such as interleukin-4 (IL-4), IL-6, IL-10, IL-11, and IL-13. Cytokines are cell-signaling molecules, which may be categorized as peptides, proteins, or glycoproteins. IL-1 receptor antagonists (IL-IRa) may also be included in the composition to reduce inflammation in the area of treatment.
- the anti-inflammatory agents may include free radical scavengers or antioxidants such as, without limitation, glutathione, selenium, vitamin E, vitamin C, and/or beta-carotene.
- Agents useful for enhancing wound healing include, but are not limited to, growth factors, collagenases, fullerenes and derivatives thereof, pseudopterosin-based compounds, histatin, anti-fibrotic compounds such as tumor growth factor-beta inhibitors, analgesics, and the like.
- the agent useful for wound healing is fibroblast growth factor (FGF).
- Agents useful for enhancing angiogenesis and/or vasculogenesis include, but are not limited to, growth factors, matrix mealloproteinases (MMPs), and angiopoietins (Ang1 and Ang2).
- the growth factors useful in the present composition include the vascular endothelial growth factor (VEGF) family including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PGF), and the FGF family (FGF-1 and FGF-2).
- VEGF vascular endothelial growth factor
- the agent useful for enhancing angiogenesis and/or vasculogenesis is selected from the VEGF family
- the pH a composition of the present invention is preferably from about 6.4 to about 8.3, optimally 7.4.
- art-known pH buffer solutions such as sodium phosphate or bicarbonate, may be used.
- Excipients may be used to bring the solution to isotonicity, such as, sodium chloride.
- Other pharmaceutically acceptable agents can also be used to bring the composition to isotonicity, for example, dextrose, propylene glycol, polyols (e.g., mannitol and sorbitol) or other solutes, including basic solutes or acidic solutes in the penis.
- composition of the present invention may further include a biologic matrix or growth scaffold on which the adipose tissue and stem cells are present.
- the matrix is a degradable matrix, such that after implantation, the matrix is slowly dissolved by the body's natural processes.
- a scaffold may include collagen fibers or bundles, for example the Three Dimensional Collagen Composite Scaffold available from Becton, Dickinson and Company.
- Other scaffolds may be formed from isolated components of ECM, or whole ECM.
- Such scaffolds are available, for example, from Kensey Nash under the trade name MESO BIOMATRIXTM and include porcine mesothelial ECM.
- the stem cells are then able to discriminate between normal and abnormal collagen and create new normal collagen and repair old collagen, in Peyronie's plaques, vascular fibrosis, and allow normal angiogenesis with normal blood vessels being created. Also the growth factors of amnion reactivate the penis's own stem cells allowing them to restore vasculogenesis and digest Peyronie's plaques.
- scaffolds made from synthetic materials may also be used in the composition of the present invention. These scaffolds may be provided by any known process familiar to those in the polymer arts.
- the synthetic scaffold may include a fabric that can be attached to the site of interest by sutures or the like, or a may be held in place by an adhesive that is acceptable for use in humans. Such scaffolds can be formed into any suitable shape.
- the composition is provided on an ECM scaffold.
- the ECM may be obtained from any commercial source.
- the ECM scaffold may be biodegradable or not, but preferably is biodegradable.
- the adipose tissue and at least one isolated stem cell may be disposed on the surface of the scaffold, or may be embedded within a three-dimensional scaffold. Formation of such scaffolds, through dissociation of tissue, digestion, lyophilization, and reconstitution, may be accomplished by any procedure known to those of skill in the art.
- the scaffold is a fibrin scaffold that is injectable, for example through the method also provided herein.
- injectable fibrin scaffolds are known in the art, for example, a group has seen growth of cardiac cells following implantation of ADRCs on a fibrin scaffold via injection. Zhang et al, Preservation of the cardiac function in infracted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds. Exper. Biol . & Med. 2010; 235: 1505-1515.
- Another aspect of the current invention provides for a method of treating an individual having a penile defect.
- the method comprises providing a composition of at least one isolated stem cell, and implanting the composition within the penis of the individual.
- the method may be used for treatment of erectile dysfunction (ED) and Peyronie's disease, among other defects or disorders.
- ED erectile dysfunction
- Peyronie's disease among other defects or disorders.
- the implanting step comprises providing a biological scaffold or matrix comprising the composition.
- suitable biological scaffolds are known to those skilled in the art.
- the matrix is a degradable matrix, such that after implantation, the matrix is slowly dissolved by the body's natural processes.
- the composition is provided on an ECM scaffold, for example, from Kensey Nash under the trade name MESO BIOMATRIXTM, and that scaffolding is then implanted into the subject.
- ECM scaffold may be biodegradable or not.
- the composition is implanted into a subject by injection.
- the pellet of cells obtained by the method provided herein is resuspended in a suitable solution and injected into appropriate areas of the body.
- the implantation is directed toward the subject's penis.
- Implantation into the penis may be at any suitable location or anatomy for addressing the particular defect.
- Implantation may be of the composition, including in some embodiments adipose tissue and/or a scaffold or matrix, by injection of a solution, or by any other method known for introducing stem cells to a target.
- injection occurs at the target site and is in at least 50 micro liter volumes delivered in a needle of suitable gauge for the anatomy.
- the composition is implanted into or around the subject's tunica albuginea.
- Stem cells such as ADRCs in a embodiment, stimulate the growth of human tissues. Wounded tissue is most often replaced by scar tissue, such as that present in Peyronie's disease. This scar tissue is characterized in the skin by disorganized collagen structure and irregular vascular structure. Stem cells reorganize collagen and induce vasculogenesis, aiding in wound healing, such as in wounds present in Peyronie's disease.
- Proliferation and/or differentiation of cells may be accomplished before or after transplantation, and in various combinations of in vitro or in vivo conditions, including (1) proliferation and differentiation in vitro, then transplantation, (2) proliferation in vitro, transplantation, then further proliferation and differentiation in vivo, and (3) proliferation in vitro, transplantation and differentiation in vivo.
- Those skilled in the art can follow standard methodology to transform the stem cells of the current invention into a desired cell type or engineered construct for use in implantation for the purposes described herein.
- the penile stem cells may be activated by known methods in the art, such as centrifugation, vibration, shock waves, or light.
- penile stem cells and compositions described herein can be used for other penile defects, such as urethral stricture disease and fistula and hypospadias repair and incontinence bulking surgery or trauma from injury—scar from fracture or priapism or trauma or in emergency room setting in a priapism case.
- a composition of the present invention is administered to subjects having Peyronie's disease (PD).
- Peyronie's disease is an ailment involving the growth of fibrous scar tissue, or plaques, in the soft tissue of the penis, which results in abnormal bending of the organ. The etiology of the plaques is not known. These plaques grow in the tunica albuginea, a region of connective tissue that is part of the more general connective tissue of Buck's fascia. The tunica albuginea is an area surrounding the corpora cavemosa. The disease results in pain, erectile dysfunction (ED), and alteration of penis shape, and may be caused by disorganized collagen fibers.
- Treatments for the disease currently include administration of corticosteroids to the plaques, radiation therapy, and vitamin E Pharmaceuticals for treatment exist; however, the use of medicaments is considered controversial.
- baseline measurements are taken to assess the state of health of the subjects. These assessments include the following:
- Penile doppler is a standard tool for the evaluation of ED, and is less invasive than typical means for measuring artery velocity, angiography with selective internal iliac angiography.
- Penile Doppler may be performed with a high frequency transducer (7.5-9.0 MHz), and at least the inner diameter of the cavernosal artery, baseline peak systolic velocity, and end diastolic velocity are measured.
- a normal value for inner diameter of the cavernosal artery is 0.3-0.5 mm.
- a flaccid state monophasic flow should be seen in an individual without Peyronie' s disease.
- a velocity of greater than 30 cm/sec should be observed in an individual without ED, which is often a symptom of Peyronie' s disease.
- the size of fibrous plaques present on the penis is also assessed prior to the initiation of any treatment. This may be done with ultrasound, at which time the grade of Peyronie's may be assigned to the subject. Peyronie's grades are given according to the following: Grade 1 (plaque less than 0.3 cm), Grade 2 (greater than 0.3 cm and less than 1.5 cm), and Grade 3 (greater than 1.5 cm, or two plaques greater than 1 cm).
- Curvature may be assigned a grade according to the following, based on the Kelami classification system: Grade 1 (curvature of 30 degrees or less), Grade 2 (curvature of 30 degrees to 60 degrees), and Grade 3 (curvature of greater than 60 degrees).
- a penile rigidity test is also performed prior to initiation of treatment. This test may be done as a nocturnal penile tumescence (NPT test) or an intracavernosal injection test.
- NPT test nocturnal penile tumescence
- the ring-like device is a simple mechanical device consisting of plastic films, which shear at certain pressures, for example when an erection provides sufficient pressure on the ring to break the film.
- the electronic measurement includes a device that measures frequency, temporal length, and rigidity of erections during sleep. This is a preferred means for measuring rigidity.
- These variations of the NPT test may be conducted in a polysomnography or other sleep lab, or at the subject's home. The NPT test is usually performed over two consecutive nights for accuracy.
- alprostodil a formulation of prostaglandin El available under the trade names EDEX® from actient pharmaceuticals and CAVERJECT® from Pfizer
- Tri-Mix a mixture of Prostaglandin E1, Phentolamine, and Papaverine
- Subjects are also given the International Index of Erectile Function (IIEF) Questionnaire prior to initiation of treatment.
- IIEF International Index of Erectile Function
- This questionnaire asks subjects to rate various parameters relating to ED by answering fifteen questions, and assigns point values from zero to five to each answer.
- a score of 25-30 indicates no ED, and a score of 0-6 indicates severe ED.
- a continuum of moderate to mild ED exists between a score of 7 and 24.
- a shortened version of the IIEF the IIEF-5 may be administered. In this short form, five questions are to be answered, and a score of 22-25 means that the subject does not have ED, and a score of 5-7 means the subject has severe ED.
- a continuum of moderate to mild ED exists between a score of 7 and 22.
- a composition including stem cells is administered to the subject by implantation in the penis.
- This implantation is by surgical incision and implantation with a biodegradable scaffold having stem cells present therein, by injection of the composition on an injectable fibrin scaffold, or injection of the stem cells alone, or with an injectable fibrin scaffold.
- Various groups including other elements such as growth factors, anti-inflammatories, antioxidants, and collagenases are included. Injections are made into the tunica albuginea surrounding the corpora cavernosa and/or the corpora cavernosa themselves, any artery feeding penile tissue, or the corporal arteries or internal pudendal arteries. Repeated injections may be necessary.
- follow-up observations including each of the aforementioned variables (arterial velocity, penile plaque size, penile curvature, IIEF score, and rigidity testing) are collected at three months, six months, and twelve months. Increased velocity, decreased plaque size, decreased curvature, increased IIEF score, and increased rigidity are expected. Shortening of time for improvement is expected in those receiving collagenase as well.
- a composition of the present invention is administered to subjects having erectile dysfunction (ED).
- ED is an ailment in which a male is unable to achieve or sustain an erection suitable for sexual intercourse.
- a number of factors are believed to play a role in or be directly responsible for ED, including obesity, blood pressure, chronic illnesses such as diabetes, poor blood flow to the penis, smoking tobacco, alcoholism, and side-effects of other medications.
- Treatments for ED currently include cessation of potential causes such as smoking tobacco and consumption of alcohol, hormone (testosterone) replacement, surgery, and administration of pharmaceuticals such as vardenafil, tadalafil, and sildenafil.
- Some of these pharmaceuticals are controversial for their incompatibility with nitrate drugs, and for their unwanted side-effects, such as effects on vision (blurring, loss of vision) and priapism.
- baseline measurements are taken to assess the state of health of the subjects. These assessments include the following:
- Subjects will have peak penile artery velocity in the corporal arteries measured with penile doppler and ultrasound, as discussed above. In a flaccid state, monophasic flow should be seen. In an erect state, a velocity of greater than 30 cm/sec should be observed in an individual without ED.
- a penile rigidity test is also performed prior to any initiation of treatment. This test may be done as a nocturnal penile tumescence (NPT test) or an intracavernosal injection test, as discussed above.
- NPT test nocturnal penile tumescence
- intracavernosal injection test Another form of the rigidity test is the intracavernosal injection test, which as discussed above, involves injection of alprostadil (a formulation of prostaglandin E) available under the trade names EDEX® from actient pharmaceuticals and CAVERJECT® from Pfizer) or Tri-Mix (a mixture of Prostaglandin E1, Phentolamine, and Papaverine) into the base of the penis causing an erection. Following the injection, fullness and length of the erection are measured. The length and circumference of each subject's penis is also assessed prior to treatment.
- alprostadil a formulation of prostaglandin E
- Tri-Mix a mixture of Prostaglan
- IIEF International Index of Erectile Function
- a composition including stem cells is administered to the subject by implantation in the penis.
- This implantation is by surgical incision and implantation with a biodegradable scaffold having stem cells present therein, by injection of the composition on an injectable fibrin scaffold, or injection of adipose tissue and stem cell alone.
- Various groups including other elements such as growth factors, anti-inflammatories, antioxidants, and collagenases are included. Injections are made into the tunica albuginea surrounding the corpora cavernosa and/or the corpora cavernosa themselves, any artery feeding penile tissue, or the corporal arteries or internal pudendal arteries. Repeated injections may be necessary.
- follow-up observations including each of the aforementioned variables (arterial velocity, rigidity testing, and IIEF score) are collected at three months, six months, and twelve months. Increased velocity, increased IIEF score, and increased rigidity are expected.
- ED erectile dysfunction
- PD Peyronie's Disease
- penile fibrotic trauma patients with erectile dysfunction (ED), Peyronie's Disease (PD) and penile fibrotic trauma were selected. They were given an artificial erection with Tri-Mix (a mixture of Prostaglandin E1, Phentolamine, and Papaverine), which allows the corpora cavernosum and the cavernosa spaces to fill and be pressurized with blood. The stem cells are believed to live in the crevices of the corpora.
- Tri-Mix a mixture of Prostaglandin E1, Phentolamine, and Papaverine
- a large bore needle was inserted into the corpora cavernosa and aspirated to obtain 60 cc of blood and blood products.
- the blood and blood products were centrifuged (e.g., in a centrifuge used for deriving platelet rich plasma or for separating bone marrow stem cells from the fluid derived from a bone marrow aspiration) to separate the fluid into different cell layers, including a layer of mononuclear cells and platelet rich plasma.
- the platelet rich plasma layer was extracted and collected, which provided 10 mL of blood product substantially free of red blood cells, which was rich in growth factors and penile stem cells.
- the mononuclear cell layer was also extracted since it is expected to have penile stem cells.
- This fluid containing the penile stem cells had a cell count of ⁇ 10 6 mononuclear cells, which is 2-5 times greater than normal plasma.
- the cells were plated and grown. Stem cells were found to be present in a higher concentration then is found in typical blood. Flow cytometry was performed to further characterize the penile stem cells (See Table 1).
- the fluid was evenly injected into both corpora cavernosum.
- the fluid was injected into both corpora and around and in all of the penile plaques and abnormal areas of the tunica albiginea.
- the fluid is injected it in both corpora and in the fibrotic areas.
- the priapism In a patient with an active priapism, the priapism is drained the same technique of centrifuging and reinjecting the cells is performed.
Abstract
Description
- The present invention relates to compositions for use in medical procedures, methods for use thereof, and methods of preparation thereof. More specifically, the invention relates to compositions including stem cells, such as penile stem cells, useful for regenerating tissue, improving vasculogenesis and angiogenesis in disease and improving wound healing, specifically in penile disease and defects.
- Use of stem cells has grown exponentially over the past two decades as methods of isolating and purifying these cells has become simpler and more cost-effective. In particular, with the advent of the ability to obtain adult stem cells, as opposed to politically-charged embryonic stem cells, work in the field has blossomed. Stem cells have been suggested as a cure for ailments ranging from Parkinson's disease (replacing dying dopaminergic cells of the substantia nigra) to myocardial infarctions and cardiomyopathy. Gimble J M et al., Circulation Res. 2007; 100: 1249-1260; Kondo K et al., Arteriosclerosis, Thrombosis, and Vascular Biol. 2009; 29: 61-66.
- Other defects and diseases may also be candidates for stem cell intervention. One area of interest is that of penile defects, such as erectile dysfunction (ED) and Peyronie's disease (PD). At least some forms of ED trace their etiology to vascular deficits in the penile tissue. Pharmaceutical compositions for treating ED do exist; however, a need exists for a treatment that does not require use of medicaments. At least one group has reported success in the use of stem cells derived from bone marrow to reverse ED in an animal model. Kendirci M et al., J. Urol. 2010; 184(4): 1560-1566. Another group has seen success in using muscle-derived stem cells in a rat model of ED. Woo J C et al., Korean J. Urol. 2011; 52: 359-363.
- Peyronie's disease (PD) is an ailment involving the growth of fibrous plaques in the soft tissue of the penis. These plaques grow in the tunica albuginea, a region of connective tissue that is part of the more general connective tissue of Buck's fascia. The tunica albuginea is an area surrounding the corpora cavernosa. The disease results in pain, ED, scarring, and alteration of penis shape, and may be caused by disorganized collagen fibers. Treatments for the disease currently include administration of corticosteroids to the plaques, radiation therapy, and vitamin E Pharmaceuticals for treatment exist; however, the use of medicaments is considered controversial in the art, and these compounds have not met with sustained success. Hauck E W et al., European Urology 2006; 49(6): 987-97. The newest medication is Clostridium Histolyticum Collagenase which has potentially harmful side effects.
- In light of the above, a need exists in the art for compositions, such as compositions of stem cells, that are easy to obtain and isolate, methods for obtaining such stem cells, and methods for using stem cells in treating penile defects.
- In one aspect, provided herein are compositions that comprise a population of isolated penile stem cells substantially free of red blood cells. In some embodiments, the penile stem cells are derived from a donor. In some embodiments, the penile stem cell is mixed with amniotic fluid.
- In another aspect, provided herein are compositions that comprise adipose tissue and isolated stem cells. In some embodiments, the isolated stem cells are a population of isolated penile stem cells substantially free of red blood cells. In some embodiments, the penile stem cell is derived from a donor, either alive or dead, such as a cadaver. In some embodiments, the isolated stem cells include stem cells placental or embryonic in origin. In other embodiments, the isolated stem cells include mesenchymal stem cells. In certain embodiments, the isolated stem cells include adipose-derived stem and regenerative cells (ADRC). In further embodiments, the stem cells and adipose tissue are derived from a donor.
- In additional embodiments, the compositions include at least one additional additive. The additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis. In further embodiments, the compositions include a growth scaffold. In some embodiments, the penile stem cells are mixed with amnion and/or amniotic fluid, or growth factors, or testosterone, or human chorionic gonadotropin (HCG), or human growth hormone (HGH) or a combination thereof.
- In another aspect, provided herein are methods of treating a penile defect in a subject, comprising providing a composition that includes a population of isolated penile stem cells, and implanting the composition within the penis of the subject. In some embodiments, the penile stem cells are derived from the subject. In some embodiments, the penile stem cells are mixed with amnion and/or amniotic fluid. In certain embodiments, the compositions comprise adipose tissue and stem cells, preferably penile stem cells that are derived from the subject. In some embodiments, the compositions include stem cells placental or embryonic in origin. In other embodiments, the penile stem cells are mesenchymal stem cells. In certain further embodiments, the compositions include ADRC. In further embodiments, the adipose tissue and ADRC are derived from the subject. In some embodiments, the composition is implanted into the subject's penis. In further embodiments, the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In another aspect, provided herein are methods of treating a penile defect in a subject, comprising providing a composition that includes amnion and/or amniotic fluid, and implanting the composition within the penis of the subject. In some embodiments, the compositions include stem cells placental or embryonic in origin. In other embodiments, the penile stem cells are mesenchymal stem cells. In some embodiments, the composition is implanted into the subject's penis. In further embodiments, the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In additional embodiments, the compositions that are implanted include at least one additional additive. The additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis. In further embodiments the composition includes an implantable or injectable growth scaffold, or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action.
- The present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising at least one penile stem cell, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment. The present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising amnion and/or amniotic fluid, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment.
- In another aspect, provided herein are methods of obtaining penile stem cells substantially free of red blood cells, the methods comprising the steps of: providing a whole blood specimen obtained from the penis of a subject; separating the whole blood into fractions, wherein one fraction contains penile stem cells and a second fraction containing substantially all of the red blood cells from the specimen; and collecting the fraction containing the penile stem cells.
- Other features and advantages of the present invention will become apparent from the following detailed description and examples. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
- In one aspect, provided herein are compositions that comprise a population of isolated penile stem cells substantially free of red blood cells. In some embodiments, the penile stem cells are derived from a donor or cadaver. In some embodiments, the penile stem cell is mixed with amniotic fluid. In some embodiments, the cells are cultured and grown and then reinjected.
- In another aspect, provided herein are compositions that comprise adipose tissue and isolated stem cells. In some embodiments, the isolated stem cells are a population of isolated penile stem cells substantially free of red blood cells. In some embodiments, the penile stem cell is derived from a donor or cadaver. In some embodiments, the isolated stem cells include stem cells placental or embryonic in origin. In other embodiments, the isolated stem cells include mesenchymal stem cells. In certain embodiments, the isolated stem cells include adipose-derived stem and regenerative cells (ADRC). In further embodiments, the stem cells and adipose tissue are derived from a donor.
- In additional embodiments, the compositions include at least one additional additive. The additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis. In further embodiments, the compositions include a growth scaffold or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action. In some embodiments, the penile stem cell is mixed with amniotic fluid.
- In another aspect, provided herein are methods of treating a penile defect in a subject, comprising providing a composition that includes a population of isolated penile stem cells, and implanting the composition within the penis of the subject. In some embodiments, the penile stem cells are derived from the subject. In some embodiments, the penile stem cells are mixed with amnion and/or amniotic fluid. In certain embodiments, the compositions comprise adipose tissue and stem cells, preferably penile stem cells that are derived from the subject. In some embodiments, the compositions include stem cells placental or embryonic in origin. In other embodiments, the penile stem cells are mesenchymal stem cells. In certain further embodiments, the compositions include ADRC. In further embodiments, the adipose tissue and ADRC are derived from the subject. In some embodiments, the composition is implanted into the subject's penis. In further embodiments, the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In another aspect, provided herein are methods of treating a penile defect in a subject, comprising providing a composition that includes amnion and/or amniotic fluid, and implanting the composition within the penis of the subject. In some embodiments, the compositions include stem cells placental or embryonic in origin. In other embodiments, the penile stem cells are mesenchymal stem cells. In some embodiments, the composition is implanted into the subject's penis. In further embodiments, the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In additional embodiments, the compositions that are implanted include at least one additional additive. The additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis. In further embodiments the composition includes an implantable or injectable growth scaffold, or a viscosity or scaffold that allows for a time-release or delayed release mechanism of action.
- The present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising at least one penile stem cell, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment. The present invention also provides methods of treating Peyronie's disease, erectile dysfunction or penile trauma by injecting a composition comprising amnion and/or amniotic fluid, at least one component of extracellular matrix, and at least one growth factor, and injecting that composition into the tunica albuginea or corpora cavernosum of a subject in need of treatment. In some embodiments, the extracellular matrix component(s) and/or growth factor(s) are placental or embryonic, amniotic or chorionic, or cadaveric in origin.
- In another aspect, provided herein are methods of obtaining penile stem cells substantially free of red blood cells, the methods comprising the steps of: providing a whole blood specimen obtained from the penis of a subject; separating the whole blood into fractions, wherein one fraction contains penile stem cells and a second fraction containing substantially all of the red blood cells from the specimen; and collecting the fraction containing the penile stem cells.
- In some embodiments, the stem cells are penile stem cells derived from the subject. In some embodiments, the penile stem cell is mixed with amniotic fluid. In certain embodiments, the composition comprises adipose tissue and stem cells, preferably penile stem cells, which may be derived from the subject. In some embodiments, the compositions include one or more additional types of stem cells. In some embodiments, the additional types of stem cells are placental or embryonic in origin. In other embodiments, the additional types of stem cells are mesenchymal stem cell. In certain further embodiments, the additional types of stem cells are ADRCs In further embodiments, the adipose tissue and ADRC are derived from the subject. In some embodiments, the composition is implanted into the subject's penis. In further embodiments, the composition is implanted into or around the subject's corpus cavernosum. In another embodiment, the composition is implanted into or around the subject's tunica albuginea. In certain embodiments the composition is injected into the tissue of interest. In other embodiments the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In additional embodiments, the composition that is implanted includes at least one additional additive or is only an additive of growth factors such as amniotic fluid. The additive may be a compound useful in wound healing, in decreasing inflammation, in breaking down collagen, or in promoting angiogenesis and/or vasculogenesis. In further embodiments the composition includes an implantable or injectable growth scaffold.
- Penile stem cells may be used to advantageously promote vasculogenesis and wound healing in penile defects. These properties function to address defects and diseases such as ED. Additionally, penile stem cells may be provided directly to plaques in Peyronie's disease, stimulating wound healing. Penile stem cells are preferable for stem cell derived treatments of these defects because of their ability to stimulate vasculogenesis and to produce organized collagen.
- In some embodiments, a composition of the present invention includes testosterone.
- In some embodiments, a composition of the present invention includes human chorionic gonadotropin (hCG).
- In some embodiments, a composition of the present invention includes human growth hormone (HGH) or somatropin.
- In some embodiments, a composition of the present invention includes collagen.
- For convenience, certain terms employed in the entire application (including the specification, examples, and appended claims) are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- It is to be understood that this invention is not limited to the particular methodology, protocols, cell lines or type of stem cell, constructs, additives, and reagents described herein. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
- The term “stem cell” refers to any multipotent or pluripotent cell, traditional stem cells, progenitor cells, preprogenitor cells, and reserve cells. These cells include Mesenchymal Stem Cells, Hematopoietic Stem Cells, Endothelial Stem Cells, and Pericytes. The term is used interchangeably with and may mean progenitor cell. A stem cell may be derived from an adult organism or from a cell line, or from an embryonic organism. Exemplary stem cells include embryonic stem cells, adult stem cells, pluripotent stem cells, neural stem cells, liver stem cells, muscle stem cells, muscle precursor stem cells, endothelial progenitor cells, bone marrow stem cells, chondrogenic stem cells, lymphoid stem cells, mesenchymal stem cells, hematopoietic stem cells, and the like. Descriptions of stem cells, including method for isolating and culturing them, may be found in, among other places, Embryonic Stem Cells, Methods and Protocols, Turksen ed., Humana Press, 2002.
- The term “adult” as used herein refers to any non-embryonic organism. For example the term “adult adipose-derived regenerative cell,” refers to an adipose-derived regenerative cell, other than that obtained from an embryo.
- The term “embryo” as used herein refers to any multicellular diploid eukaryote during development, until birth or hatching. The term “embryonic stem cell” refers to a pluripotent cell derived from the inner cell mass of a blastocyst.
- The term “mesenchymal stem cell” refers to any multipotent stromal cell derived from, for example and without limitation, umbilical cord blood, adipose tissue, muscle, comeal stroma, and dental pulp that can differentiate into cells such as, including but not limited to, osteoblasts, chondrocytes, and adipocytes.
- The term “adipose-derived regenerative cell” (ADRC) is used interchangeably with adipose stem cells (ASC) herein and refers to adult cells that originate from adipose tissue. ADRC are a heterologous population of cells comprising at least one of the following population of cells; adult stem cells, vascular endothelial cells, vascular smooth muscle cells, endothelial cells, mesenchymal stem cells, fibroblasts, pericytes and additional other cell types.
- In some embodiments, ADRC refers to a substantially pure population of adipose-derived stem cells. ADRC can be easily harvested from adipose tissue and are substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The stromal vascular fraction cells are substantially devoid of extracellular matrix material from adipose tissue. ADRC may also be referred to as adipose-derived stem/stromal cells (ASCs), adipose-derived adult stem (ADAS) cells, adipose-derived adult stromal cells, adipose-derived stromal cells, adipose stromal cells, adipose mesenchymal cells, adipose-derived mesenchymal stem cells, lipoblasts, pericytes, preadipocytes, and processed lipoaspirate cells.
- The term “adipose” as used herein refers to any fat tissue from a subject. The terms “adipose” and “adipose tissue” are used interchangeably herein. The adipose tissue may be brown fat, white fat or yellow fat or white adipose tissue, derived from subcutaneous, omental/visceral, mammary, gonadal, or other adipose tissue site. The adipose tissue has adipocytes and stroma. Adipose tissue is found throughout the body of an animal. For example, in mammals, adipose tissue is present in the omentum, bone marrow, subcutaneous space, and surrounding most organs. Such cells may comprise a primary cell culture or an immortalized cell line. The adipose tissue may be from any organism having fat tissue.
- Preferably, the adipose tissue is human; most preferably, the adipose tissue is derived from the individual in need of treatment for a penile defect. A convenient source of adipose tissue is from liposuction surgery, however, the source of adipose tissue or the method of isolation of adipose tissue is not critical to the invention, and acquisition of adipose tissue by any means may adequately provide tissue and stem cells for the present invention.
- The term “tissue” as used herein is a broad term that is applied to any group of cells that perform specific functions, and includes in some instances whole organs and/or part of organs. A tissue need not form a layer, and thus encompasses a wide range of tissue, including adipose tissue derived from any source in an organism. Preferably, the tissue is derived from a mammal. Most preferably, the tissue is derived from the individual in need of treatment for a penile defect.
- The term “implant” as used herein refers to any method for transferring a population of cells or cell mass into a subject, including by surgical implantation (incision into the tissue of interest and deposition therein) and injection by a syringe, needle, cannula, or the like of any suitable gauge. An implant as used herein can comprise genetically modified cells, as well as cells differentiated from other cells, such as stem cells, progenitors, and the like, as well as adipose cells or tissue.
- The term “corpus cavernosum” of the penis refers to one of a pair of sponge-like regions of erectile tissue which contain most of the blood in the penis during penile erection. Generally, the two corpus cavernosum and a corpus spongiosum are three expandable erectile tissues along the length of the penis which fill with blood during erection. The term “corpus” is used interchangeably herein with corporal, corporeal and corporic, which are terms used to describe tissues which are derived from the corpora cavernosum or which can be developed, differentiated, or altered by natural or artificial means into corpora cavernosum tissue. The term “cavernosum” is used interchangeably herein as cavernae, corporum, cavernosum, or cavernosorum penis, and refers to the caverns of corpora cavernosa (or one of the two corpus cavernosum) of the penis or the dilatable spaces within the corpus cavernosum of the penis, which fill with blood and become distended with erection.
- The term “tunica albuginea” refers to the fibrous tissue covering, or enveloping, the corpora cavernosa of the penis. This tissue consists of elastin and collagen. The term “Buck's fascia” refers to the layer of fascia covering the penis, including the tunica albuginea.
- The terms “subject” and “individual” are used interchangeably herein, and refer to an animal, for example a human, from whom stem cells, for example penile stem cells can be harvested, or a subject into whom tissue can be transplanted for treatment, for example treatment for penile defects, using the compositions and methods described herein. For treatment of conditions or disease states which are specific for a specific animal such as a human subject, the term “subject” refers to that specific animal. In some embodiments, the subject is a human subject. It is possible in embodiments of this invention that recipient subjects are of a different mammalian subject than the donor subject.
- One aspect of the present invention provides for compositions. The compositions comprise a population of isolated penile stem cells. The composition is one that is suitable for implantation into a subject, for example an animal, preferably a mammal. In a preferred embodiment, the composition is suitable for implantation into a human. In a further preferred embodiment, the at least one penile stem cell of the composition is suitable for implantation into a human because they are derived from the same human subject.
- Another aspect of the present invention provides for a composition that comprises adipose tissue and a population of isolated stem cells, such as a penile stem cell. The composition is one that is suitable for implantation into a subject, for example an animal, preferably a mammal. In a preferred embodiment, the composition is suitable for implantation into a human. In a further preferred embodiment, the adipose tissue and at least one stem cell of the composition are suitable for implantation into a human because they are derived from the same human subject.
- Stem cells include, but are not limited to, mesenchymal stem cells. The stem cells may be obtained from any suitable source, for example, and without limitation, stem cells may be obtained from adult or embryonic sources, from bone marrow, from placental tissue, from umbilical cord blood, and from adipose tissue. In preferred embodiments, the stem cell is obtained from adipose tissue, and is an adipose-derived regenerative cell (ADRC). In more preferred embodiments, the stem cell is obtained from the penis, and is a penile stem cell.
- In general, adipose tissue may be collected in any suitable manner For example, in embodiments, adipose tissue is obtained through dry liposuction, wet liposuction, super-wet liposuction, tumescent liposuction, power-assisted liposuction, laser-assisted liposuction, or the like.
- Once harvested by any suitable method, adipose tissue may be processed by known methods. The following methods are to be considered exemplary. In a preferred, embodiment, adipose tissue is processed using the STEMSOURCE® Cellbank or Cytori Celution System. The Cytori procedure and system therefore are disclosed in detail in U.S. Pat. Nos. 7,501,115 and 7,687,059. Briefly, adipose tissue is harvested from a subject. In a preferred, embodiment of the current invention, the subject is an individual in need of treatment for a penile defect. The tissue is processed to remove mature adipocytes and connective tissue from the sample. Processing may occur within a system having a tissue collection port, filter disposed within the system, and a mixing container for holding the processed sample. The filter works to remove the unwanted cells and non-cellular materials from the sample, enriching the proportion of ADRCs in the filtered sample.
- The Cytori system has successfully been used in providing ADRCs for breast tissue implantation for reconstruction after radical lumpectomy, proving the ability of stem cells isolated by this method to generate tissue of a single type (adipocytes, or fat). Similarly, in treatment of penile defects, only one type of tissue need be generated. As such, the Cytori method and system is well suited for use in preparing a composition of the current invention. With regard to use of the Cytori system and method itself, processing is accomplished by washing and disaggregating the tissue to reduce the presence of free lipids and blood elements. Processing may or may not also include a rinsing step; the step conducted using isotonic saline or any other suitable physiologic solution known to those skilled in the art.
- Remaining tissue is then disaggregated using enzyme degradation or mechanical disaggregation. The cells and solution are then centrifuged to separate cells, including ADRC, from the degradation solution. The cells form a pellet in the centrifuge, and the pellet can be frozen for storage or resuspended in another solution, for example a buffer, for use in medical treatments such as those recited herein.
- The concentration of stem cells obtained by this method may vary, but typically approximately 0.1% of the cells in the pellet are stem cells. Greater percentages may be obtained by varying the above method, for example by use of adherence protocols such as described in Berdel W E et al., Purification of human monocytes by adherence to polymeric fluorocarbon. Immunobiology 1982 163(5): 511-520, or by separation on the basis of cell-surface markers, for example on the basis of markers present on differentiated cells, such as CD34 and the like, or by selecting based on markers expressed on progenitor cells, such as CD90 and the like. In a preferred, embodiment, the percentage of stem cells present in the pellet is between approximately 2% and 12%.
- For embodiments where the individual to be treated is not the donor of the adipose tissue and the population of isolated penile stem cells the composition may further comprise immunosuppressive agents designed to prevent rejection of the composition once implanted. Immunosuppressive agents may be selected from glucocorticoids, cytostatics, antibodies, pharmaceuticals such as tacrolimus, ciclosporin, sirolimus, interferons, opioids, mycophenolic acid, fingolimod, and myriocin.
- In other embodiments adipose tissue is derived from lipoaspirate (i.e. from liposuction), is washed, exposed to a collagenase digest at 37° Celsius, and centrifuged.
- While specific penile stem cell isolation procedures are provided herein, the invention described should not be limited to those procedures. It should be apparent to those skilled in the art that other means of isolating stem cells, in particular penile stem cells, are possible and may be used interchangeably with the current invention. For example, penis stem cells can be isolated from tissue obtained from a biopsy of the penis by a variety of techniques, such as by using an 18 gauge needle biopsy gun. They can also be obtained via a trocar or needle by draining blood and fluid from an erect penis from the patient then processed, activated, and/or minimally manipulated and placed back into the subject's penis
- In some embodiments, penile stem cells may be isolated from a whole blood sample obtained from the penis of a subject by preparing and extracting the platelet rich plasma preparation, which contains the penile stem cells, from the specimen. This is a similar method used to obtaining bone marrow stem cells.
- The U.S. Food and Drug Administration has approved two methods for platelet rich plasma (PRP) preparation. Both methods involve the collection of whole blood (with the anticoagulant citrate dextrose) and two stages of centrifugation designed to separate PRP from platelet-poor plasma and red blood cells.
- Briefly, skin is prepared in a sterile manner for drawing blood. The blood is gently drawn or aspirated into an anticoagulated syringe, such as a 20 cc syringe. Care is taken to not activate the platelets or rupture the RBCs. The first spin separates red blood cells (RBC) from the PRP and the RBCs are discarded. The second spin concentrates platelets and white cells with the supernatant being platelet poor plasma (PPP), which is removed. The remaining plasma is used to resuspend the platelets and white cells. For about 60 cc of anticoagulated blood drawn and processed, about 10 cc of PRP is obtained.
- In some embodiments, the PRP can be used directly for reinjection into the penis. In some embodiments, the PRP can also be added to or enriched with other types of stem cells, such as those discussed below. In other embodiments, the PRP is centrifuged and the penile stem cells pelleted and then resuspended in a suitable media. In some embodiments, PRP or penile stem cells are mixed with growth factors such as amnion or amniotic fluid or other biologic or non-biologic growth factors, such as platelet derived growth factor or endothelial derived growth factor or testosterone, human chorionic gonadotropin (hCG), human growth hormone (HGH) or somatropin. In some embodiments, the penile stem cells are mixed with Natural Killer (NK cells) harvested from the subject. In some embodiments, the penile stem cells are resuspended with PRP containing autologous growth factors. In some embodiments, the penile stem cells are resuspended in saline, such as phosphate-buffered saline (PBS). In some embodiments, the penile stem cells are resuspended with a buffer, for example bicarbonate for a basic composition or phosphate for an acidic composition. Without wishing to be bound by theory, the NK cells can dissolve peyronie's plaques.
- The penile stem cells and compositions described herein can be injected into the penile arteries or the urethral sphincter or layered on a flap externally or internally, or injected into a stricture or fistula or into the corpora cavernosum, bulbo spongiosum, or tunica albiginea or urethra. They can also be injected during open surgery for Peyronie's disease. In some embodiments, the penile stem cells and compositions described herein are administered in the form of a gel or putty. In some embodiments, the penile stem cells and compositions described herein are injected into the penis in the form of a spray. In some embodiments, the penile stem cells and compositions described herein are formulated and administered for extended release (e.g., in the form of dissolvable capsules or pellets).
- In some embodiments, the penile stem cells are isolated, the stem cells are expanded and then administered to the subject. In the penile stem cells are isolated, formulated for long-term storage (e.g., by freezing) for use at a later date.
- In an embodiment, ADRCs are isolated from adipose tissue by triplicate washing in 0.1 mol/L phosphate-buffered saline (PBS), pH=7.4. Tissue is then minced and digested in 0.1% collagenase type I at 37 degrees Celsius for 45 minutes. Afterwards, the solution is filtered and centrifuged at 800 g for eight minutes. Supernatant is removed and cells are resuspended in Modified Eagle's Medium (MEM) supplemented with 10% fetal bovine serum (FBS). Cells are then plated and incubated at 37 degrees Celsius.
- ADRCs are harvested from the growth by flow cytometry according to traditional flow cytometry methods, for example as disclosed in Alexander C M et al., Cell Stem Cell 2009; 5: 579-83. Cells are washed in buffer (FBS) and incubated for 30 minutes in FBS with antibodies against CD105, CD90, CD34, and/or CD45. The ADRCs are then combined with adipose cells in a composition for injection.
- In embodiments, the ADRCs are processed by washing in PBS followed by ECM digestion in 0.075% collagenase for 30 minutes at 37 degrees Celsius. Digestion is neutralized using Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS. Digested tissue is then centrifuged at 1200 g for 10 minutes to obtain a cell pellet. The pellet is then resuspended and filtered, and cells are plated. Cell media is removed 12-18 hours later and fresh media provided. Cells are incubated on ice with antibodies to human CDllb, CD18, CD31, CD34, CD38, CD44, CD45, CD54, CD62L, CD90, CD105, CD106, CD117, CD133, CD144, CD166, and/or CD271. Cells are then washed and flow cytometry, for example fluorescence-activated cell sorting, is performed according to traditional, known methods, for example as disclosed in Alexander C M et al., Cell Stem Cell 2009; 5: 579-83.
- In embodiments, the stem cells used in the present composition includes mesenchymal stem cell isolated from bone marrow. In certain preferred embodiments, the bone marrow is that of the patient in need of treatment for a penile defect. Such stem cells may be isolated in accordance with the following protocol, which is to be considered exemplary.
- Bone marrow tissue may be obtained from the head of the femur, by transversally segmenting the femoral head to expose trabecular, or cancellous, bone. This trabecular bone may be extracted with successive, serial washes of phosphate-buffered saline (PBS). The solution of PBS and trabecular bone may then be filtered through a filter of any suitable pore diameter, for example and without limitation a 40, 70, or 100 um cell strainer. The solution may then be centrifuged at 400 g for 10 minutes to form a pellet of cells, the supernatant aspirated, and the pellet resuspended in media containing DMEM supplemented with 10% FBS and 1% streptomycin or penicillin, or both. Cells may then be cultured, and then washed with PBS to remove non-adherent cells. The obtained cells may be further expanded by repeating the incubation and washing steps until a suitable volume of cells is obtained. Medium may be supplemented with heparin and growth factors, if necessary.
- In other embodiments, the stem cells may be obtained from placental tissue. Stem cells from this source may be obtained by any method known to those of skill in the art. In certain embodiments, stem cells may be obtained according to the following procedure. Tissue samples from placental tissue may be washed in PBS plus antibiotic solution (200 U/mL penicillin and/or 200 mg/mL streptomycin). The amnion is separated from chorion through fine dissection. Small pieces of both membranes are minced and subjected to enzymatic digestion to obtain a mesenchymal population of cells. The resulting cells are seeded in 25 cm culture flasks with 5 mL of DMEM with 20% FBS and antibiotics (penicillin 100 U/mL and/or streptomycin 100 mg/mL), and incubated at 37 degrees Celsius.
- No adherent cells are removed with changes of medium (DMEM plus 10% FBS). The obtained cells may be further expanded by repeating the incubation and washing steps until a suitable volume of cells is obtained. Medium may be supplemented with heparin and growth factors, if necessary.
- In addition to the protocols described herein, stem cells may be obtained from a suitable commercial source for use in the compositions of the present invention. In embodiments, mesenchymal stem cells from placental tissue provided under the trade name OVATION® by Osiris Therapeutics, Inc. may be used. This product is preferred because it includes components of extracellular matrix (ECM) and growth factors.
- In certain embodiments, the composition further comprises other agents. These agents may include compositions designed to assist in reducing inflammation, aiding wound healing, promoting angiogenesis and/or vasculogenesis, and degrading collagen. Agents useful for reducing inflammation include, but are not limited to, anti-inflammatory cytokines such as interleukin-4 (IL-4), IL-6, IL-10, IL-11, and IL-13. Cytokines are cell-signaling molecules, which may be categorized as peptides, proteins, or glycoproteins. IL-1 receptor antagonists (IL-IRa) may also be included in the composition to reduce inflammation in the area of treatment. In certain embodiments, the anti-inflammatory agents may include free radical scavengers or antioxidants such as, without limitation, glutathione, selenium, vitamin E, vitamin C, and/or beta-carotene.
- Agents useful for enhancing wound healing that may be included with the composition of the present invention include, but are not limited to, growth factors, collagenases, fullerenes and derivatives thereof, pseudopterosin-based compounds, histatin, anti-fibrotic compounds such as tumor growth factor-beta inhibitors, analgesics, and the like. In preferred, embodiments, the agent useful for wound healing is fibroblast growth factor (FGF).
- Agents useful for enhancing angiogenesis and/or vasculogenesis that may be included with a composition of the present invention include, but are not limited to, growth factors, matrix mealloproteinases (MMPs), and angiopoietins (Ang1 and Ang2). The growth factors useful in the present composition include the vascular endothelial growth factor (VEGF) family including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PGF), and the FGF family (FGF-1 and FGF-2). In certain preferred embodiments, the agent useful for enhancing angiogenesis and/or vasculogenesis is selected from the VEGF family
- The pH a composition of the present invention is preferably from about 6.4 to about 8.3, optimally 7.4. To achieve a desired pH, art-known pH buffer solutions, such as sodium phosphate or bicarbonate, may be used. Excipients may be used to bring the solution to isotonicity, such as, sodium chloride. Other pharmaceutically acceptable agents can also be used to bring the composition to isotonicity, for example, dextrose, propylene glycol, polyols (e.g., mannitol and sorbitol) or other solutes, including basic solutes or acidic solutes in the penis.
- As Peyronie's disease is known to result from disorganized collagen, in certain preferred embodiments it is also useful to include a collagenase in the composition, to aid in the breaking down of disorganized collagen in the plaques associated with the disease. Collagenases are enzymes that break the peptide bonds in collagen and aid in breaking down the protein. Collagenases useful in the composition of the present invention may include MMPs and collagenase clostridial histolyticum (available from Auxilium Pharmaceuticals under the trade name XIAFLEX®).
- The composition of the present invention may further include a biologic matrix or growth scaffold on which the adipose tissue and stem cells are present. In some embodiments the matrix is a degradable matrix, such that after implantation, the matrix is slowly dissolved by the body's natural processes. Such a scaffold may include collagen fibers or bundles, for example the Three Dimensional Collagen Composite Scaffold available from Becton, Dickinson and Company. Other scaffolds may be formed from isolated components of ECM, or whole ECM. Such scaffolds are available, for example, from Kensey Nash under the trade name MESO BIOMATRIX™ and include porcine mesothelial ECM. Without wishing to be bound by theory, by administering activated stem cells with normal collagen, the stem cells are then able to discriminate between normal and abnormal collagen and create new normal collagen and repair old collagen, in Peyronie's plaques, vascular fibrosis, and allow normal angiogenesis with normal blood vessels being created. Also the growth factors of amnion reactivate the penis's own stem cells allowing them to restore vasculogenesis and digest Peyronie's plaques.
- In addition, scaffolds made from synthetic materials may also be used in the composition of the present invention. These scaffolds may be provided by any known process familiar to those in the polymer arts. The synthetic scaffold may include a fabric that can be attached to the site of interest by sutures or the like, or a may be held in place by an adhesive that is acceptable for use in humans. Such scaffolds can be formed into any suitable shape.
- In a preferred, embodiment, the composition is provided on an ECM scaffold. The ECM may be obtained from any commercial source. The ECM scaffold may be biodegradable or not, but preferably is biodegradable. In such an embodiment, the adipose tissue and at least one isolated stem cell may be disposed on the surface of the scaffold, or may be embedded within a three-dimensional scaffold. Formation of such scaffolds, through dissociation of tissue, digestion, lyophilization, and reconstitution, may be accomplished by any procedure known to those of skill in the art.
- In some embodiments, the scaffold is a fibrin scaffold that is injectable, for example through the method also provided herein. Injectable fibrin scaffolds are known in the art, for example, a group has seen growth of cardiac cells following implantation of ADRCs on a fibrin scaffold via injection. Zhang et al, Preservation of the cardiac function in infracted rat hearts by the transplantation of adipose-derived stem cells with injectable fibrin scaffolds. Exper. Biol. & Med. 2010; 235: 1505-1515.
- Another aspect of the current invention provides for a method of treating an individual having a penile defect. The method comprises providing a composition of at least one isolated stem cell, and implanting the composition within the penis of the individual. The method may be used for treatment of erectile dysfunction (ED) and Peyronie's disease, among other defects or disorders.
- In an embodiment, the implanting step comprises providing a biological scaffold or matrix comprising the composition. Examples of suitable biological scaffolds are known to those skilled in the art. In some embodiments the matrix is a degradable matrix, such that after implantation, the matrix is slowly dissolved by the body's natural processes.
- In a further preferred embodiment, the composition is provided on an ECM scaffold, for example, from Kensey Nash under the trade name MESO BIOMATRIX™, and that scaffolding is then implanted into the subject. The ECM scaffold may be biodegradable or not.
- In yet another embodiment, the composition is implanted into a subject by injection. The pellet of cells obtained by the method provided herein is resuspended in a suitable solution and injected into appropriate areas of the body.
- In preferred embodiments, the implantation is directed toward the subject's penis. Implantation into the penis may be at any suitable location or anatomy for addressing the particular defect. Implantation may be of the composition, including in some embodiments adipose tissue and/or a scaffold or matrix, by injection of a solution, or by any other method known for introducing stem cells to a target. In embodiments, injection occurs at the target site and is in at least 50 micro liter volumes delivered in a needle of suitable gauge for the anatomy.
- In further preferred, embodiments, the implantation is directed towards at least one of the subject's corpora cavemosa. In preferred, embodiments, a solution comprising the composition of isolated stem cells is injected directly into or around at least one of the corpora cavemosa. In preferred, embodiments, a solution comprising the composition of isolated stem cells, specifically isolated penile stem cells isolated as described above or Penis Platelet Rich Plasma, is injected directly into scar tissue present on the penis or into the corpora cavernosum of an individual with Peyronie's disease. In additional embodiments, the composition is injected or infused into any artery that feeds penile tissue. In certain embodiments, the composition is injected or infused into the corporal arteries or internal pudendal arteries.
- In another embodiment, the composition is implanted into or around the subject's tunica albuginea. Stem cells, such as ADRCs in a embodiment, stimulate the growth of human tissues. Wounded tissue is most often replaced by scar tissue, such as that present in Peyronie's disease. This scar tissue is characterized in the skin by disorganized collagen structure and irregular vascular structure. Stem cells reorganize collagen and induce vasculogenesis, aiding in wound healing, such as in wounds present in Peyronie's disease.
- Proliferation and/or differentiation of cells may be accomplished before or after transplantation, and in various combinations of in vitro or in vivo conditions, including (1) proliferation and differentiation in vitro, then transplantation, (2) proliferation in vitro, transplantation, then further proliferation and differentiation in vivo, and (3) proliferation in vitro, transplantation and differentiation in vivo. Those skilled in the art can follow standard methodology to transform the stem cells of the current invention into a desired cell type or engineered construct for use in implantation for the purposes described herein. The penile stem cells may be activated by known methods in the art, such as centrifugation, vibration, shock waves, or light.
- While treatment of Peyronie's disease and erectile dysfunction is discussed in detail below, the penile stem cells and compositions described herein can be used for other penile defects, such as urethral stricture disease and fistula and hypospadias repair and incontinence bulking surgery or trauma from injury—scar from fracture or priapism or trauma or in emergency room setting in a priapism case.
- A composition of the present invention is administered to subjects having Peyronie's disease (PD). Peyronie's disease is an ailment involving the growth of fibrous scar tissue, or plaques, in the soft tissue of the penis, which results in abnormal bending of the organ. The etiology of the plaques is not known. These plaques grow in the tunica albuginea, a region of connective tissue that is part of the more general connective tissue of Buck's fascia. The tunica albuginea is an area surrounding the corpora cavemosa. The disease results in pain, erectile dysfunction (ED), and alteration of penis shape, and may be caused by disorganized collagen fibers. Treatments for the disease currently include administration of corticosteroids to the plaques, radiation therapy, and vitamin E Pharmaceuticals for treatment exist; however, the use of medicaments is considered controversial.
- Prior to administration of a composition of the present invention, baseline measurements are taken to assess the state of health of the subjects. These assessments include the following:
- Subjects will have peak penile artery velocity in the corporal arteries measured with penile doppler and ultrasound. Penile doppler is a standard tool for the evaluation of ED, and is less invasive than typical means for measuring artery velocity, angiography with selective internal iliac angiography. Penile Doppler may be performed with a high frequency transducer (7.5-9.0 MHz), and at least the inner diameter of the cavernosal artery, baseline peak systolic velocity, and end diastolic velocity are measured. A normal value for inner diameter of the cavernosal artery is 0.3-0.5 mm. In a flaccid state, monophasic flow should be seen in an individual without Peyronie' s disease. In an erect state, a velocity of greater than 30 cm/sec should be observed in an individual without ED, which is often a symptom of Peyronie' s disease.
- In addition to penile artery velocity, the size of fibrous plaques present on the penis is also assessed prior to the initiation of any treatment. This may be done with ultrasound, at which time the grade of Peyronie's may be assigned to the subject. Peyronie's grades are given according to the following: Grade 1 (plaque less than 0.3 cm), Grade 2 (greater than 0.3 cm and less than 1.5 cm), and Grade 3 (greater than 1.5 cm, or two plaques greater than 1 cm).
- Angle of penile curvature, a hallmark of Peyronie's disease, is also measured prior to initiation of treatment. Curvature may be assigned a grade according to the following, based on the Kelami classification system: Grade 1 (curvature of 30 degrees or less), Grade 2 (curvature of 30 degrees to 60 degrees), and Grade 3 (curvature of greater than 60 degrees).
- A penile rigidity test is also performed prior to initiation of treatment. This test may be done as a nocturnal penile tumescence (NPT test) or an intracavernosal injection test. In an NPT test, the frequency and quality of an erection during sleep is assessed by either placing a ring-like device around the subject's penis, or by use of an electronic monitoring device. The ring-like device is a simple mechanical device consisting of plastic films, which shear at certain pressures, for example when an erection provides sufficient pressure on the ring to break the film. The electronic measurement includes a device that measures frequency, temporal length, and rigidity of erections during sleep. This is a preferred means for measuring rigidity. These variations of the NPT test may be conducted in a polysomnography or other sleep lab, or at the subject's home. The NPT test is usually performed over two consecutive nights for accuracy.
- Another form of rigidity test, the intracavernosal injection test, involves injection of alprostodil (a formulation of prostaglandin El available under the trade names EDEX® from actient pharmaceuticals and CAVERJECT® from Pfizer) or Tri-Mix (a mixture of Prostaglandin E1, Phentolamine, and Papaverine) into the base of the penis, which causes an erection through its vasodilator properties. Following the injection, fullness and length of the erection are measured. The test may be repeated as necessary for increased accuracy. The length and circumference of each subject's penis is also assessed prior to treatment.
- Subjects are also given the International Index of Erectile Function (IIEF) Questionnaire prior to initiation of treatment. This questionnaire asks subjects to rate various parameters relating to ED by answering fifteen questions, and assigns point values from zero to five to each answer. A score of 25-30 indicates no ED, and a score of 0-6 indicates severe ED. A continuum of moderate to mild ED exists between a score of 7 and 24. A shortened version of the IIEF, the IIEF-5 may be administered. In this short form, five questions are to be answered, and a score of 22-25 means that the subject does not have ED, and a score of 5-7 means the subject has severe ED. A continuum of moderate to mild ED exists between a score of 7 and 22.
- Following baseline measurements of the above variables, a composition including stem cells, preferably penile stem cells, is administered to the subject by implantation in the penis. This implantation is by surgical incision and implantation with a biodegradable scaffold having stem cells present therein, by injection of the composition on an injectable fibrin scaffold, or injection of the stem cells alone, or with an injectable fibrin scaffold. Various groups including other elements such as growth factors, anti-inflammatories, antioxidants, and collagenases are included. Injections are made into the tunica albuginea surrounding the corpora cavernosa and/or the corpora cavernosa themselves, any artery feeding penile tissue, or the corporal arteries or internal pudendal arteries. Repeated injections may be necessary.
- Following administration of the composition, follow-up observations, including each of the aforementioned variables (arterial velocity, penile plaque size, penile curvature, IIEF score, and rigidity testing) are collected at three months, six months, and twelve months. Increased velocity, decreased plaque size, decreased curvature, increased IIEF score, and increased rigidity are expected. Shortening of time for improvement is expected in those receiving collagenase as well.
- A composition of the present invention is administered to subjects having erectile dysfunction (ED). ED is an ailment in which a male is unable to achieve or sustain an erection suitable for sexual intercourse. A number of factors are believed to play a role in or be directly responsible for ED, including obesity, blood pressure, chronic illnesses such as diabetes, poor blood flow to the penis, smoking tobacco, alcoholism, and side-effects of other medications.
- Treatments for ED currently include cessation of potential causes such as smoking tobacco and consumption of alcohol, hormone (testosterone) replacement, surgery, and administration of pharmaceuticals such as vardenafil, tadalafil, and sildenafil. Some of these pharmaceuticals are controversial for their incompatibility with nitrate drugs, and for their unwanted side-effects, such as effects on vision (blurring, loss of vision) and priapism.
- Prior to administration of a composition of the present invention, baseline measurements are taken to assess the state of health of the subjects. These assessments include the following:
- Subjects will have peak penile artery velocity in the corporal arteries measured with penile doppler and ultrasound, as discussed above. In a flaccid state, monophasic flow should be seen. In an erect state, a velocity of greater than 30 cm/sec should be observed in an individual without ED.
- A penile rigidity test is also performed prior to any initiation of treatment. This test may be done as a nocturnal penile tumescence (NPT test) or an intracavernosal injection test, as discussed above. Another form of the rigidity test is the intracavernosal injection test, which as discussed above, involves injection of alprostadil (a formulation of prostaglandin E) available under the trade names EDEX® from actient pharmaceuticals and CAVERJECT® from Pfizer) or Tri-Mix (a mixture of Prostaglandin E1, Phentolamine, and Papaverine) into the base of the penis causing an erection. Following the injection, fullness and length of the erection are measured. The length and circumference of each subject's penis is also assessed prior to treatment.
- As discussed above, subjects are also given the International Index of Erectile Function (IIEF) Questionnaire—or shortened version of the IIEF, the IIEF-5 —prior to initiation of treatment.
- Following baseline measurements of the above variables, a composition including stem cells, preferably penile stem cells, is administered to the subject by implantation in the penis. This implantation is by surgical incision and implantation with a biodegradable scaffold having stem cells present therein, by injection of the composition on an injectable fibrin scaffold, or injection of adipose tissue and stem cell alone. Various groups including other elements such as growth factors, anti-inflammatories, antioxidants, and collagenases are included. Injections are made into the tunica albuginea surrounding the corpora cavernosa and/or the corpora cavernosa themselves, any artery feeding penile tissue, or the corporal arteries or internal pudendal arteries. Repeated injections may be necessary.
- Following administration of the composition, follow-up observations, including each of the aforementioned variables (arterial velocity, rigidity testing, and IIEF score) are collected at three months, six months, and twelve months. Increased velocity, increased IIEF score, and increased rigidity are expected.
- Patients with erectile dysfunction (ED), Peyronie's Disease (PD) and penile fibrotic trauma were selected. They were given an artificial erection with Tri-Mix (a mixture of Prostaglandin E1, Phentolamine, and Papaverine), which allows the corpora cavernosum and the cavernosa spaces to fill and be pressurized with blood. The stem cells are believed to live in the crevices of the corpora.
- After applying local anesthesia to each patient, a large bore needle was inserted into the corpora cavernosa and aspirated to obtain 60 cc of blood and blood products. The blood and blood products, were centrifuged (e.g., in a centrifuge used for deriving platelet rich plasma or for separating bone marrow stem cells from the fluid derived from a bone marrow aspiration) to separate the fluid into different cell layers, including a layer of mononuclear cells and platelet rich plasma. The platelet rich plasma layer was extracted and collected, which provided 10 mL of blood product substantially free of red blood cells, which was rich in growth factors and penile stem cells. The mononuclear cell layer was also extracted since it is expected to have penile stem cells.
- This fluid containing the penile stem cells had a cell count of ˜106 mononuclear cells, which is 2-5 times greater than normal plasma. The cells were plated and grown. Stem cells were found to be present in a higher concentration then is found in typical blood. Flow cytometry was performed to further characterize the penile stem cells (See Table 1).
-
TABLE 1 CFU-F CFU-F D34+ D146+ TNC/mL Frequency per mL D34+ % cells/mL D146+ % cell/mL 12/22- 9.55 × 106 0 0 no data no data no data no data Sample 1 12/22- 11.3 × 106 1/250,000 45 no data no data no data no data Sample 2 12/22- x x x x x x x Sample 3 2/6-BM 1 20.6 × 106 1/250,000 82.6 8.09% 3.06 × 105 1.51% 31.2 × 104 2/6-Penis 8.75 × 106 0 0 6.16% 5.39 × 105 0.57% 4.99 × 104 PRP 1 2/6-Penis 5.56 × 106 0 0 6.52% 3.63 × 105 1.05% 5.84 × 104 PRP 2 4/17-Penis 36.5 × 106 TBD TBD x x x x PRP 1 4/17-Penis 18.9 × 106 TBD TBD x x x x PRP 2 4/17-Penis 10.3 × 106 TBD TBD x x x x PRP 3 Typical 800 k- 0 0 1-4% 105-105 Not in Not in Whole Blood 4 million literature literature Typical PRP 5-20 0 0 2-7% 105-105 Not in Not in million literature literature Typical BMA 1-10 1/75,000 100- 3-8% 105-105 Not in Not in million 1000/mL literature literature Typical BMC 20-100 1/50,000 1000- 4-12% 106-107 Not in Not in million 5000/mL literature literature Collagenase Digested Biopsy Tissue TNC CFU-F per CFU-F per D34+ D146+ punch Freq. punch CD34+ % cells/mL D146+ % cell/mL 2/6-Tissue 6.75 ×104 1/30,000 2.3 Not Not Not Not Biopsy enough enough enough enough 4 punches cells cells cells cells 4/17 Patient All TBD TBD Not Not Not Not 1 Tissue Punches enough enough enough enough 2.36 × 105 cells cells cells cells 4/17 Patient All TBD TBD Not Not Not Not 3 Tissue Punches enough enough enough enough 2.8 × 105 cells cells cells cells - Each patient was given an artificial erection. The fluid containing the penile stem cells was injected back into the erect penis of the patient from which it was derived. Since the patient had an artificial erection the cellular material was able to stay in the penis without the need for a penile clamp to keep the fluid in. If the penis had gone flaccid, a penile ring or clamp could have been used to keep the fluid in.
- For the erectile dysfunction patient, the fluid was evenly injected into both corpora cavernosum.
- For the Peyronie's Disease patient, the fluid was injected into both corpora and around and in all of the penile plaques and abnormal areas of the tunica albiginea.
- For the penile trauma patient and/or patient with Priapism, the fluid is injected it in both corpora and in the fibrotic areas.
- The patients were examined at two and three weeks after the procedure. The patients showed much improvement with them getting erections more often. Furthermore, the Peyronie's Disease patient no longer had pain associated with erections; the fibrotic trauma patient had a softer penis.
- In a patient with an active priapism, the priapism is drained the same technique of centrifuging and reinjecting the cells is performed.
- While the present invention has been described in connection with the preferred embodiments, it is to be understood that other similar embodiments may be used or modifications and additions may be made to the described embodiments for performing the same function of the present invention without deviating therefrom. Therefore, the present invention should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the appended claims.
Claims (70)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/541,988 US20180028575A1 (en) | 2012-01-30 | 2016-02-08 | Methods and compositions for treatment of penile defects |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261592108P | 2012-01-30 | 2012-01-30 | |
US201562112709P | 2015-02-06 | 2015-02-06 | |
US15/541,988 US20180028575A1 (en) | 2012-01-30 | 2016-02-08 | Methods and compositions for treatment of penile defects |
PCT/US2016/016934 WO2016127153A1 (en) | 2015-02-06 | 2016-02-08 | Methods and compositions for treatment of penile defects |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/016934 A-371-Of-International WO2016127153A1 (en) | 2012-01-30 | 2016-02-08 | Methods and compositions for treatment of penile defects |
US16/711,673 Continuation-In-Part US11160835B2 (en) | 2012-01-30 | 2019-12-12 | Methods and compositions for treatment of penile defects |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/363,142 Continuation-In-Part US10751374B2 (en) | 2012-01-30 | 2013-01-30 | Methods and compositions for treatment of penile defects |
PCT/US2013/023830 Continuation-In-Part WO2013116327A1 (en) | 2012-01-30 | 2013-01-30 | Methods and compositions for treatment of penile defects |
US17/017,122 Division US20200405774A1 (en) | 2015-02-06 | 2020-09-10 | Methods and compositions for treatment of penile defects |
US17/103,248 Continuation US20210077538A1 (en) | 2012-01-30 | 2020-11-24 | Methods and compositions for treatment of penile defects |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180028575A1 true US20180028575A1 (en) | 2018-02-01 |
Family
ID=74869191
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/541,988 Abandoned US20180028575A1 (en) | 2012-01-30 | 2016-02-08 | Methods and compositions for treatment of penile defects |
US16/175,042 Active 2034-03-20 US11324780B2 (en) | 2012-01-30 | 2018-10-30 | Amniotic fluid composition and method of using |
US17/103,248 Pending US20210077538A1 (en) | 2012-01-30 | 2020-11-24 | Methods and compositions for treatment of penile defects |
US17/717,479 Pending US20220233606A1 (en) | 2012-01-30 | 2022-04-11 | An amniotic fluid composition and method of using |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/175,042 Active 2034-03-20 US11324780B2 (en) | 2012-01-30 | 2018-10-30 | Amniotic fluid composition and method of using |
US17/103,248 Pending US20210077538A1 (en) | 2012-01-30 | 2020-11-24 | Methods and compositions for treatment of penile defects |
US17/717,479 Pending US20220233606A1 (en) | 2012-01-30 | 2022-04-11 | An amniotic fluid composition and method of using |
Country Status (1)
Country | Link |
---|---|
US (4) | US20180028575A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006053093A2 (en) | 2004-11-08 | 2006-05-18 | Cluster Resources, Inc. | System and method of providing system jobs within a compute environment |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
ES2545385T3 (en) | 2001-12-07 | 2015-09-10 | Cytori Therapeutics, Inc. | System for processing lipoaspirated cells |
WO2007149548A2 (en) | 2006-06-22 | 2007-12-27 | Medistem Laboratories, Inc. | Treatment of erectile dysfunction by stem cell therapy |
AU2009228203B2 (en) | 2008-03-26 | 2014-11-20 | Ams Research Corporation | Treatment of pelvic floor disorders with an adipose-derived cell composition |
US8727965B2 (en) | 2010-03-05 | 2014-05-20 | Tissue Genesis, Inc. | Methods and compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells |
EP2926821B1 (en) | 2010-03-05 | 2019-12-25 | Tissue Genesis, LLC | Compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells |
US9180172B2 (en) * | 2010-12-15 | 2015-11-10 | Ams Research Corporation | Treatment of Peyronies disease |
US20120183519A1 (en) | 2011-01-13 | 2012-07-19 | Biomet Biologics, Llc | Treatment of erectile dysfunction using platelet-rich plasma |
WO2013116327A1 (en) | 2012-01-30 | 2013-08-08 | Zahalsky Michael P | Methods and compositions for treatment of penile defects |
US20150335681A1 (en) * | 2014-05-22 | 2015-11-26 | Microaire Surgical Instruments, Llc | Biocomposites Having Viable Stem Cells and Platelets and Methods for Making and Using the Same |
-
2016
- 2016-02-08 US US15/541,988 patent/US20180028575A1/en not_active Abandoned
-
2018
- 2018-10-30 US US16/175,042 patent/US11324780B2/en active Active
-
2020
- 2020-11-24 US US17/103,248 patent/US20210077538A1/en active Pending
-
2022
- 2022-04-11 US US17/717,479 patent/US20220233606A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11324780B2 (en) | 2022-05-10 |
US20190060372A1 (en) | 2019-02-28 |
US20220233606A1 (en) | 2022-07-28 |
US20210077538A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11160835B2 (en) | Methods and compositions for treatment of penile defects | |
Bao et al. | C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner | |
KR101922538B1 (en) | Process, tube and device for the preparation of wound healant composition | |
US10111906B2 (en) | Serum fraction of platelet-rich fibrin | |
KR101920891B1 (en) | Bone marrow derived cd271 precursor cells for cardiac repair | |
US7785582B2 (en) | Use of synovium and omentum for tissue engineering | |
CN108472319B (en) | Transplantation material for treating heart disease | |
US20170296700A1 (en) | Stem cell compositions, systems and uses thereof | |
CN110904037A (en) | Extraction method and application of exosome derived from amniotic mesenchymal stem cells | |
JP7108541B2 (en) | Kit for preparing therapeutic agent for disease, therapeutic agent for disease, and method for preparing therapeutic agent for disease | |
US20210077538A1 (en) | Methods and compositions for treatment of penile defects | |
JP2016524954A (en) | Allogeneic valves produced by biotechnology | |
US20170136152A1 (en) | Gonad-derived side population stem cells | |
US20200405774A1 (en) | Methods and compositions for treatment of penile defects | |
US11497791B1 (en) | Isolated placental stem cell recruiting factors | |
Taguchi | Regenerative Medicine for Tendon/Ligament Injuries: De Novo Equine Tendon/Ligament Neotissue Generation and Application | |
CN115300625A (en) | Composite preparation for improving thickness of endometrium | |
Bank | TRANSPLANTATION AND CELLULAR ENGINEERING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |